BETHESDA, MD — The US Food and Drug Administration (FDA) has approved the evolocumab (Repatha, Amgen) Pushtronex system, the first once-monthly delivery option for a proprotein convertase subtilisin ...

Biotech giant Amgen (NASDAQ: AMGN) announced yesterday that the FDA has approved the Repatha Pushtronex system. This new system is a pre-filled, on-body medical device that allows for monthly, ...

Repatha is a drug intended to treat patients with high cholesterol. The Pushotronex system offers a new, monthly single-dose administration option for the drug. The device, created in conjunction with ...

Amgen said the FDA has approved its Repatha (evolocumab) Pushtronex system, the first hands-free, once-monthly delivery option for a PCSK9 inhibitor. Evolocumab is indicated as an adjunct to diet and ...